Logo
x

Search

Subscribe Now

novo nordisk

Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes

Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes

  • January 20, 2025
Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases

Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases

  • January 9, 2025
Novo Nordisk’s Alhemo Receives the US FDA’s Approval as a Prophylactic Treatment of Hemophilia A or B with Inhibitors

Novo Nordisk’s Alhemo Receives the US FDA’s Approval as a Prophylactic Treatment of Hemophilia A or B with Inhibitors

  • December 27, 2024
Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeting

Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeti...

  • November 20, 2024
Novo Nordisk’s Alhemo Gains the CHMP’s Positive Opinion as a Prophylatic Treatment of Hemophilia A or B

Novo Nordisk’s Alhemo Gains the CHMP’s Positive Opinion as a Prophylatic Treatment of Hemophilia A or B

  • October 17, 2024
Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B

Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B

  • March 26, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.